Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.